Skip to main content

Treatment Clinical Trials for Non-Small Cell Lung Cancer

Review the non-small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 463

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1047 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 456 locations
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People with Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment with Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 413 locations
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 421 locations
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Status: Active
Location: 550 locations
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Status: Active
Location: 280 locations
Immunotherapy after Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Status: Active
Location: 279 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 263 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 260 locations
Testing Osimertinib as a Treatment for Lung Cancers with an EGFR Exon 20 Change
Status: Active
Location: 254 locations
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer with Remaining Lymph Node Cancer After Treatment
Status: Active
Location: 99 locations
Testing Targeted Radiotherapy while Continuing Ongoing Immunotherapy (with or without Chemotherapy) versus Continuing Immunotherapy or Switching to a Different Chemotherapy for Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 81 locations
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, after Surgery to Prevent Early Stage Non-small Cell Lung Cancer from Returning, AASI-NSCLC Trial
Status: Active
Location: 70 locations
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Status: Active
Location: 55 locations
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Status: Active
Location: 30 locations
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Status: Active
Location: 35 locations
Treatment for Advanced Non-small Cell Lung Cancer with Actionable Genomic Alterations after Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 34 locations
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Status: Active
Location: 26 locations
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Status: Active
Location: 24 locations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 35 locations
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Status: Active
Location: 23 locations
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Status: Active
Location: 22 locations
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Status: Active
Location: 21 locations
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Status: Active
Location: 22 locations
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Status: Active
Location: 23 locations